# PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms

> **NCT05670821** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 52 (actual)

## Conditions studied

- Generalized Pustular Psoriasis

## Interventions

- **DRUG:** Spesolimab

## Key facts

- **NCT ID:** NCT05670821
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-18
- **Primary completion:** 2025-10-06
- **Final completion:** 2025-10-06
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05670821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05670821, "PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05670821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*